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The HLA-B*5701 allele is predictive of hypersensitivity reac-
tion to abacavir, a response herein termed “ABC-HSR.” This
study of 1103 individuals infected with human immunodefi-
ciency virus assessed the usefulness of genotyping a HCP5
single-nucleotide polymorphism (SNP), rs2395029, in rela-
tion to ABC-HSR. In populations with European ancestry,
rs2395029 is in linkage disequilibrium with HLA-B*5701. The
HCP5SNP was present in all 98HLA-B*5701–positive individ-
uals and was absent in 999 of 1005 HLA-B*5701–negative in-
dividuals. rs2395029 was overrepresented in 25 individuals
with clinically likely ABC-HSR, compared with its frequency
in 175 ABC-tolerant individuals (80% vs. 2%, respectively;
P<.0001). Therefore, HCP5 genotyping could serve as a sim-
ple screening tool for ABC-HSR, particularly in settings where
sequence-based HLA typing is not available.
The nucleoside-analogue reverse-transcriptase inhibitor aba-
cavir (ABC) is a widely used antiretroviral drug. Although ABC
has a favorable long-term toxicity profile, it is associated with
hypersensitivity reaction—a response herein termed “ABC-
HSR”—in 5%–8% of ABC recipients [1]. Retrospective studies
indicate a strong association between ABC-HSR and the pres-
ence of the major histocompatibility complex (MHC) class I
allele HLA-B*5701 [2, 3] in chromosome 6. The usefulness of
genetic screening for the purpose of reducing the incidence of
ABC-HSR has been demonstrated in white populations [4], and
it has been confirmed in the large randomized PREDICT-1 trial
[5]. In the latter study, the negative predictive value of HLA-
B*5701was 96% for clinically suspectedABC-HSR and 100% for
immunologically confirmedABC-HSR. Therefore, screening for
HLA-B*5701 before initiation of ABC therapy is recommended
in settings where HLA typing is available [5].
The current gold standard in screening forHLA-B*5701 is the
sequence-based genotyping method. Its universal use is limited
because it requires specialized laboratories and is labor intensive;
in addition, its relatively high costs are not always covered by
health insurance. Alternative HLA-typing methods include
polymerase chain reaction sequence-specific primer (PCR-SSP)
assay and flow cytometry [6, 7]. One report has suggested that
sequence variation in HIV-1 reverse transcriptase be used as a
marker of HLA-B*5701 carriage [8]. However, none of these
alternative techniques shows 100% concordance with the results
of sequence-based HLA typing, and they cannot reliably differ-
entiate between HLA-B*5701 and closely related HLA-B alleles
(e.g.,HLA-B*5702,HLA-B*5703, andHLA-B*5801) that are not
associated with ABC-HSR.
Recently, de Bakker at al. described a perfect linkage disequi-
librium (r2  1.0) between the rs2395029 SNP in theHLA com-
plex P5 gene (HCP5) located 100 kb centromeric of HLA-B on
chromosome 6 and HLA-B*5701 [9]; this degree of association
also had been found by a previous genomewide association anal-
ysis [10]. Prompted by these findings, we assessed, in a larger
population, the pattern of linkage disequilibrium between
rs2395029 (herein also referred to as “HCP5 SNP”) and HLA-
B*5701, and we analyzed the usefulness of HCP5 genotyping in
providing an alternative marker that would allow cheaper and
less labor-intensive screening of individuals at risk for ABC-
HSR.
Patients and methods. The HCP5 SNP genotype and the
HLA-B alleles were analyzed in 1103 participants in the Swiss
HIV Cohort Study (http://www.shcs.ch/). All patients gave in-
formed consent for genetic testing. HCP5 genotyping was per-
formed by use of either custom TaqMan SNP genotyping assays
(Applied Biosystems) or the HumanHap550 BeadChip (Illu-
mina), as we have described elsewhere [10]. High-resolution
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HLA typing was performed by sequence-based methods, as de-
scribed elsewhere [11].
The specificity and sensitivity ofHCP5 genotyping for the pre-
diction of ABC-HSR was assessed by comparison of ABC-
tolerant subjects versus individuals whose ABC treatment had
been discontinued because of presumed ABC-HSR. Individuals
with presumed ABC-HSR were identified within the Swiss HIV
Cohort Study database, which reports the reason for discontin-
uation of antiretroviral therapy in all participants. The clinical
diagnosis of ABC-HSR was reassessed in 108 individuals, on the
basis of standardized clinical criteria [1–3]. A diagnosis of ABC-
HSR required that at least 2 of the following symptoms occur6
weeks after initial exposure to ABC: fever, rash, and gastrointes-
tinal (nausea or vomiting), respiratory, or constitutional symp-
toms. On the basis of the characteristics and the time at onset of
these symptoms, as well as the use of comedication, 2 experi-
enced HIV clinicians blinded to the HLA-typing results inde-
pendently classified suspected ABC-HSR on a scale between3
(definitive ABC-HSR) and3 (ABC-HSR highly unlikely). The
mean score was used for analysis; cases were classified as clini-
cally unlikely ABC-HSR (mean score2), clinically uncertain
ABC-HSR (mean score 1 and 1), and clinically likely
ABC-HSR (mean score 2). ABC tolerance was defined as
ABC treatment for6 weeks without signs of ABC-HSR.
Results and discussion. Of the 1103 study participants, 98
wereHLA-B*5701positive, and 104 carried theHCP5 SNP (table
1). All HLA-B*5701–positive individuals were HCP5 SNP posi-
tive. The HCP5 SNP was present in 6 of 1005 HLA-B*5701–
negative individuals. Discrepant results were confirmed by inde-
pendent analysis. The sensitivity of the HCP5 SNP for the
carriage of HLA-B*5701 was 100% (95% confidence interval
[CI], 96%–100%); its specificity was 99% (95%CI, 99%–100%).
In this study population, the HCP5 SNP had a negative predic-
tive value of 100% (95% CI, 99%–100%), and a positive predic-
tive value of 94% (95% CI, 88%–98%), for carriage of HLA-
B*5701.
In the evaluation of the 6 discrepant results, we first assessed
the HLA alleles that are closely related to HLA-B*5701 (i.e.,
HLA-B*5702, HLA-B*5703, and HLA-B*5801), for linkage dis-
equilibriumwith theHCP5 SNP. TheHCP5 SNP was found in 1
of the 6 HLA-B*5703–positive individuals and in 0 of the 24
HLA-B*5801–positive individuals; there were no HLA-B*5702–
positive individuals in this cohort. For the additional 5 tests that
had results that were discrepant for HCP5, the associated HLA
types were B*1801-4901, B*4102-7301, B*0702-1501, B*0702-
4901, and B*4415-4415. It is expected that HCP5 SNP–positive
HLA-B*5701–negative individuals will not be at risk for ABC-
HSR, because carriage of HLA-B*5701 is necessary—although
not sufficient—for susceptibility to immunologically confirmed
ABC-HSR [5]. Indeed, since the completion of the current
study, 3 patients with discordance (HLA-B*5701 negative and
HCP5 positive) have started treatment with ABC and have not
experienced HSR.
Of the 108 individuals whose treatment with ABC had been
discontinued because of presumed ABC-HSR, the latter was
classified as being clinically likely in 25 (23%), clinically unlikely
in 33 (30%), and clinically uncertain in 50 (46%). In the subset
of 283 ABC-exposed individuals, the HCP5 SNP and HLA-
B*5701were perfectly correlated (r2  1.0) (table 2). TheHCP5
SNP was significantly overrepresented in individuals with likely
ABC-HSR, compared with it frequency in those with clinically
uncertain or clinically unlikely ABC-HSR (80% vs. 28% and 3%,
respectively; P  .0001, by 2 test). Of the ABC-tolerant indi-
viduals, 2% carried theHCP5 SNP—a frequency that compares
well with the results of the PREDICT-1 trial, which found that
2.4% of the individuals whom it studied wereHLA-B*5701 pos-
itive and ABC tolerant [5].
Although the present study did not identify anyHLA-B*5701–
positive HCP5 SNP–negative individuals, such a discordance
could potentially result in ABC exposure in patients who are at
increased risk for ABC-HSR, if screening were based on HCP5
genotyping alone. Resequencing of theMHCregion of 138HLA-
B*5701–positive individuals in a combined analysis of various
Table 2. Frequency of carriers of the HCP5
single-nucleotide polymorphism in the subset
of 283 abacavir (ABC)–exposed patients.
Response to ABC
Frequency of HCP5
rs2395029
Tolerance (n  175) 3 (2)
Hypersensitivity reaction
Unlikely (n  33) 1 (3)
Uncertain (n  50) 14 (28)
Likely (n  25) 20 (80)
NOTE. Data are no. (%) of patients. In the overall
population in the present study, the HCP5 single-
nucleotide polymorphism and the HLA-B*5701 allele
were perfectly (100%) correlated.
Table 1. Overall correlation between the HCP5
rs2395029 single-nucleotide polymorphism and the
HLA-B*5701 allele.
HCP5 rs2395029 status
HLA-B*5701 status
Present Absent
Present 98 6
Absent 0 99.9
NOTE. Data are % of correlation between HCP5
rs2395029 minor allele and HLA-B*5701. The mean (95%
confidence interval) values for the HCP5 single-nucleotide
polymorphism as a marker for HLA-B*5701 are as fol-
lows: sensitivity, 100% (96.3%–100%); specificity,
99.4% (98.7%–99.8%); positive predictive value, 94.2%
(87.9%–97.9%); and negative predictive value, 100%
(99.6%–100%).
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studies identified recombination events at multiple sites, sug-
gesting that there is incomplete linkage disequilibrium between
HLA-B*5701 and other MHC markers examined, including
HCP5 12. Specifically, the PREDICT-1 trial identified 2 HLA-
B*5701–positive individuals who did not carry theHCP5 SNP; 1
of them experienced ABC-HSR (as evidenced by clinical symp-
toms and a skin-patch test reaction positive for ABC), and the
other 1 was excluded, because ofHLA-B*5701 status, from treat-
ment (A. R. Hughes, personal communication).
The possibility of discordance between the HCP5 SNP and
HLA-B*5701 should be discussed in the context of (1) the reli-
ability of HLA-typing results in routine settings, (2) the general
availability of HLA typing in the various countries in which the
studies are conducted, (3) turnaround time, and (4) cost consid-
erations. Sequence-basedHLA typing remains the gold standard
for identification ofHLA-B*5701; however, its widespread use is
limited by relatively high costs and by the need for specialized
laboratories. A recent quality assessment and proficiency testing
of 7 laboratories showed accurate reporting ofHLA-B*5701 sta-
tus by PCR-SSP [13]. Although the interlaboratory variance did
not affect the accuracy of PCR-SSP, inspection of the agarose-gel
images provided by the various laboratories illustrates the neces-
sity for thorough quality-control procedures. Flow-cytometry
assays [7] offer a cheap alternative with a short turnaround time;
however, because they cannot reliably differentiate between
HLA-B*5701 and closely related HLA alleles, subsequent molec-
ular HLA typing is necessary. Variation in the HIV-1 sequence
provides a cheap way to identify HLA-B*5701, but its positive
predictive value in this regard is only 20% [8].
HCP5 SNP genotyping based on allelic discrimination offers
several advantages over other approaches toHLA-B typing. Var-
ious broadly used technologies (e.g., Taq Man platforms) allow
the standardized identification of 2 distinct sequences in 1 reac-
tion tube, limiting the risk of contamination and allowing high-
throughput genotyping that has high sensitivity and specificity.
In addition, the test is largely independent of both the perfor-
mance of and interpretation by laboratory personnel. SNP ge-
notyping is also less time consuming and cheaper than
sequence-based HLA typing, and it does not require specialized
laboratories.
In conclusion, the presence of HCP5 rs2395029 shows very
high concordance with HLA-B*5701 positivity, and, in ABC-
exposed individuals, the HCP5 SNP is highly associated with
ABC-HSR. If the high sensitivity thatHCP5 SNP genotyping has
for bothHLA-B*5701 and ABC-HSR can be confirmed by other
studies, this method could serve as a simple and cheap screening
tool for the prediction of ABC-HSR, particularly in settings
where sequence-based high-resolution HLA typing is not avail-
able. However, it is important to note that, in the present study’s
cohort, neither the presence of the HCP5 SNP nor the presence
of theHLA-B*5701 allele identified all individuals with clinically
likely ABC-HSR. Clinicians should therefore be aware that ge-
netic screening to assess the risk for ABC-HSR should never be
considered to be a substitute for appropriate clinical vigilance
regarding patients who are starting ABC treatment.
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